Dimethyl Fumarate (DMF) Fails to Slow ALS Progression in Trial

Dimethyl Fumarate (DMF) Fails to Slow ALS Progression in Trial

308327

Dimethyl Fumarate (DMF) Fails to Slow ALS Progression in Trial

Dimethyl fumarate or DMF — an oral therapy approved for multiple sclerosis (MS) — was well-tolerated among adults with amyotrophic lateral sclerosis (ALS) but failed to significantly slow disease progression or to improve survival and quality of life in these patients, according to data from a Phase 2 trial. Treatment with DMF was associated with reduced motor neuron damage relative to a placebo, but this difference was not statistically significant. While these findings support an…

You must be logged in to read/download the full post.